Answers are grounded in this paper and cite their sources.
Randomized trial reveals prolonged survival with first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, indicating superior efficacy over chemotherapy alone.
The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .).
No takes yet. Share an insight, caveat, or question.
Horn et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: